Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RET C634R RET Y806C||Advanced Solid Tumor||resistant||Vandetanib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).||19029224|
|RET V804M RET Y806C||Advanced Solid Tumor||decreased response||Selpercatinib||Preclinical - Biochemical||Actionable||In a preclinical study, transformed human cells expressing RET V804M and Y806C in cis were less sensitive to Retevmo (selpercatinib) in culture (PMID: 35304457).||35304457|
|RET V804M RET Y806C||thyroid gland medullary carcinoma||not applicable||N/A||Guideline||Risk Factor||Compound germline RET V840M and Y806C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).||detail...|
|RET V804M RET Y806C RET M918T||Advanced Solid Tumor||predicted - resistant||Selpercatinib||Preclinical - Biochemical||Actionable||In a preclinical study, transformed human cells expressing RET M918T, V804M, and Y806C in cis were resistant to Retevmo (selpercatinib) in culture (PMID: 35304457).||35304457|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|